SCLP vs. PRTC, HZD, FARN, VRP, AVCT, ARIX, CIR, BVXP, 4BB, and TILS
Should you be buying Scancell stock or one of its competitors? The main competitors of Scancell include PureTech Health (PRTC), Horizon Discovery Group plc (HZD.L) (HZD), Faron Pharmaceuticals Oy (FARN), Verona Pharma plc (VRP.L) (VRP), Avacta Group (AVCT), Arix Bioscience (ARIX), Circassia Group (CIR), Bioventix (BVXP), 4basebio (4BB), and Tiziana Life Sciences (TILS). These companies are all part of the "biotechnology" industry.
Scancell vs. Its Competitors
PureTech Health (LON:PRTC) and Scancell (LON:SCLP) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability.
PureTech Health presently has a consensus target price of GBX 455, suggesting a potential upside of 266.34%. Given PureTech Health's stronger consensus rating and higher possible upside, equities analysts clearly believe PureTech Health is more favorable than Scancell.
In the previous week, PureTech Health's average media sentiment score of 0.00 equaled Scancell'saverage media sentiment score.
79.9% of PureTech Health shares are held by institutional investors. Comparatively, 46.5% of Scancell shares are held by institutional investors. 15.9% of PureTech Health shares are held by company insiders. Comparatively, 5.0% of Scancell shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Scancell has lower revenue, but higher earnings than PureTech Health. Scancell is trading at a lower price-to-earnings ratio than PureTech Health, indicating that it is currently the more affordable of the two stocks.
PureTech Health has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500. Comparatively, Scancell has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500.
Scancell has a net margin of 0.00% compared to PureTech Health's net margin of -17,620.94%. Scancell's return on equity of 98.74% beat PureTech Health's return on equity.
Summary
PureTech Health beats Scancell on 9 of the 13 factors compared between the two stocks.
Get Scancell News Delivered to You Automatically
Sign up to receive the latest news and ratings for SCLP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SCLP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Scancell Competitors List
Related Companies and Tools
This page (LON:SCLP) was last updated on 8/29/2025 by MarketBeat.com Staff
MarketBeat All Access